CU Cancer Center member Manali Kamdar, MD, discussed 5-year follow-up data from the TRANSCEND-NHL-001 trial at ASH 2024, showcasing liso-cel’s curative potential for third-line relapsed/refractory large B-cell lymphoma. The trial demonstrated a 38% overall survival rate at 5 years with a manageable safety profile, solidifying liso-cel as a pivotal CAR T-cell therapy.